Does Edwards Lifesciences Corporation (EW) Have More Gas After Achieving All-Time High?

March 18, 2018 - By Henry Gaston

The stock of Edwards Lifesciences Corporation (NYSE:EW) reached all time high today, Mar, 18 and still has $155.15 target or 9.00 % above today’s $142.34 share price. This indicates more upside for the $29.90B company. This technical setup was reported by If the $155.15 PT is reached, the company will be worth $2.69B more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events.

The stock increased 0.88% or $1.24 during the last trading session, reaching $142.34. About 1.95M shares traded or 54.52% up from the average. Edwards Lifesciences Corporation (NYSE:EW) has risen 15.41% since March 18, 2017 and is uptrending. It has underperformed by 1.29% the S&P500.

Analysts await Edwards Lifesciences Corporation (NYSE:EW) to report earnings on April, 24. They expect $1.10 EPS, up 17.02 % or $0.16 from last year’s $0.94 per share. EW’s profit will be $231.03M for 32.35 P/E if the $1.10 EPS becomes a reality. After $0.94 actual EPS reported by Edwards Lifesciences Corporation for the previous quarter, Wall Street now forecasts 17.02 % EPS growth.

Edwards Lifesciences Corporation (NYSE:EW) Ratings Coverage

Among 28 analysts covering Edwards Lifesciences Corp (NYSE:EW), 22 have Buy rating, 1 Sell and 5 Hold. Therefore 79% are positive. Edwards Lifesciences Corp had 106 analyst reports since July 30, 2015 according to SRatingsIntel. The rating was maintained by Guggenheim with “Buy” on Friday, February 2. Barclays Capital maintained it with “Overweight” rating and $155 target in Friday, February 2 report. The firm has “Equalweight” rating by Barclays Capital given on Wednesday, July 27. BTIG Research upgraded it to “Buy” rating and $115 target in Monday, April 4 report. As per Friday, January 8, the company rating was initiated by SunTrust. The rating was maintained by Stifel Nicolaus with “Buy” on Wednesday, April 26. On Thursday, February 1 the stock rating was maintained by BMO Capital Markets with “Buy”. The company was maintained on Thursday, February 1 by Cowen & Co. The stock of Edwards Lifesciences Corporation (NYSE:EW) earned “Buy” rating by Canaccord Genuity on Thursday, July 27. Canaccord Genuity maintained the shares of EW in report on Friday, December 8 with “Buy” rating.

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. The company has market cap of $29.90 billion. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and their delivery systems for the nonsurgical replacement of heart valves. It has a 52.72 P/E ratio. The firm also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral replacement, and minimally invasive aortic heart valve system; and tissue heart valves and repair products, which are used to replace or repair a patientÂ’s diseased or defective heart valve.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.